In silico study of potential anti-SARS cell entry phytoligands from Phlomis aurea: a promising avenue for prophylaxis

Amira R Khattab*,1, Mohamed Teleb**,2 & Mohamed S Kamel1,3,4
1Pharmacognosy Department, College of Pharmacy, Arab Academy for Science, Technology & Maritime Transport, Alexandria, 1029, Egypt
2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt
3Pharmacognosy Department, Faculty of Pharmacy, Deraya University, Minia, 61111, Egypt
4Pharmacognosy Department, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt
*Author for correspondence: Dr.amira.khattab@aast.edu
**Author for correspondence: mohamedtelebismail@gmail.com

Aim: The severity of COVID-19 has raised a great public health concern evoking an urgency for developing multitargeted therapeutics. Phlomis species was ethno-pharmacologically practiced for respiratory ailments. Materials & methods: An array of 15 phytoligands previously isolated from Phlomis aurea were subjected to molecular docking to explore their potential SARS-CoV-Spike-angiotensin-converting enzyme 2 complex inhibition, that is essential for virus entry to host cell. Results: Acteoside (11) showed the most potent in silico inhibition with an additional merit, over hesperidin (16), of not binding to angiotensin-converting enzyme 2 with well proven in vivo pulmonary protective role in acute lung injury, followed by chrysoeriol-7-O-β-glucopyranoside (12) and luteolin-7-O-β-glucopyranoside (14). Conclusion: Phytoligands (11, 12 and 14) were posed as promising candidates with potential prophylactic action against COVID-19. These phytoligands were prioritized for further biological experimentation because of their acceptable predicted ADME and drug-likeness parameters. Moreover, they could aid in developing multitargeted strategy for better management of COVID-19 using phytomedicines.

Graphical abstract:

First draft submitted: 31 January 2021; Accepted for publication: 24 September 2021; Published online: 29 October 2021

Keywords: ACE2 • molecular docking • Phlomis aurea • SARS-CoV-2 • spike protein

SARS-CoV-2, an enveloped-virus possessing single-stranded, positive-sense RNA genome, is the causative agent of the rapidly evolving novel COVID-19 which raises an immense public health concern worldwide. The SARS-
CoV membrane comprises of four structural proteins viz. S (spike), E (envelope) and M (membrane) proteins that create viral envelope and N (nucleocapsid) proteins that hold the viral RNA genome. These proteins are responsible for the critical step in viral infection which is the viral entry to the host cells. SARS-CoV invades human cells through the main envelope embedded spike (S) glycoprotein which contains a receptor binding domain. Receptor binding domain then binds to the metallopeptidase on host cells, angiotensins converting enzyme-2 (ACE-2) [1]. The structural investigation of SARS-CoV-Spike-ACE2 complex and the viral entry mechanism aided in better understanding the disease pathogenesis and developing vaccines to prevent SARS-CoV-2 infection as well as therapeutic drugs [2]. As of today, no specific clinically proven antiviral drugs available for COVID-19 treatment; hence, computational efforts are still ongoing for the in silico exploration of promising drug candidates [3].

On the other side, the development of an effective SARS-CoV-2 vaccine is essential to provide an effective and economical way to prevent the viral infection and stop its transmission. These vaccines are mostly made with inactivated and attenuated viral protein particles, viral vectors and viral DNA/RNAs. Unfortunately, vaccine preclinical and clinical trials and production typically require a lengthy process which is additionally challenged by the high mutation rate of SARS-CoV-2 (about 25 mutations per year) and the diversified antigenic sequence of SARS-CoV-2 virus [4]. Accordingly, the findings of the in silico studies are considered a magic bullet for medicinal chemists to accelerate the development of preventive and therapeutic drugs for the virulent SARS-CoV-2 viral infection. Such drugs can provide valuable preventive and therapeutic intervention until an effective vaccine is produced [5].

Several research endeavors are still ongoing to find drug leads that can target host receptor or viral proteins for COVID-19 management [6–9]. Natural therapeutic agents that can block the first step of viral infection, in other words, viral entry, by preventing its binding with ACE2, are considered an important class of antiviral therapeutics that can also be of prophylactic potential. Only few S-protein-ACE2 binding inhibitors have been reported up till now, among which tetra-O-galloyl-β-D-glucose, emodin and hesperidin [1,10].

Phlomis species (Lamiaceae family), is one of the endemic plants to Saint Katharine mountain (southern Sinai, Egypt) that was described by Dioscorides as herbal medicine and ethno-pharmacologically practiced for respiratory ailment treatment [11]. Besides, many Phlomis species were used in Anatolian folk medicine as an antimicrobial, antimalarial, immunosuppressive and as a stimulant [12]. Phlomis species are also well reported to exhibit anti-infective activities, reduce fever, treat cough and throat infections among which P. caucasica Rech. F and P. cephalotes Roth (malarial fever) [13]. However, a very limited number of reports exists on the antiviral potential of Phlomis species, except for P. pungens var. pungens against parainfluenza (PI-3) RNA virus [14]. A wide array of phytochemical classes was identified in Phlomis genus viz. iridoids, lignans, flavonoids, alkaloids, phenylpropanoids, monoterpenes, diterpenoids and their glycosides [15].

Our strategy in the discovery of natural anti-SARS-CoV-2 therapeutics is contemplated by searching for drug candidates that can block the critical early step in viral infection viz. viral cell entry. Accordingly, we performed docking simulation for an array of 15 phytoligands, previously isolated from Phlomis aurea Decne (Syn.: P. flavescens Miller and P. angustifolia Miller) (Figure 1) [15], in order to predict their relative antiviral potential to interrupt the interaction between human ACE2 receptor and viral spike protein. Further, in silico prediction of physicochemical properties, absorption, distribution, metabolism, excretion and toxicity (ADMET) and drug-likeness parameters of Phlomis phytoligands were achieved.

Materials & methods
Phytoligands under study

In silico exploration was performed on an array of 15 phytoligands (Figure 1) previously isolated from leaves of Phlomis aurea Decne from Saint Katharine mountain (Sinai, Egypt) which belonged to different phytochemical classes viz. iridoids, in other words, 3-epiphlomurin (1), phlomurin (2), auroseide (5), lamide (6), 8-epiloganin (7) and ipolamiide (8), megastigmame glucoside, in other words, phlomuroside (3), benzyl alcohol glycoside, in other words, benzyl alcohol-O-β-xylopyranosyl-(1→2)-β-glucopyranoside (4), phenolic glycosides, in other words, syringin (9) and acteoside (11), phenylethanoid glycoside, in other words, 2-phenylethyl-O-β-xylopyranosyl-(1→2)-β-glucopyranoside (10), flavonoids, in other words, chrysoeriol-7-O-β-glucopyranoside (12), acacetin-7-O-β-glucopyranoside (13) and luteolin-7-O-β-glucopyranoside (14) and lignin, in other words, liriodendrin (15) [15]. 2D structures of the phytoligands (1–15) were downloaded as structure-data file from PubChem (https://pubchem.ncbi.nlm.nih.gov).
**Docking simulation**

Molecular operating environment (MOE) software (version 2015.10, Chemical Computing Group, QC, Canada) was employed for docking simulations using the crystal structure of SARS-CoV-2 spike (S) protein C-terminal domain (SARS-CoV-2-CTD) in complex with human ACE2 (hACE2). SARS-CoV-Spike-ACE2 complex reported to reveal the most recently known hACE2-binding mode was retrieved from the protein data bank (PDB ID: 6LZG) [16]. The complex was prepared by eliminating the unwanted residues, solvents and ligands using the default settings of the ‘structure preparation’ module. The spatial arrangement of some key residues in the SARS-CoV-2-CTD binding interface was located as the receptor site utilizing ‘site finder’ feature of MOE, where the site number 8 was selected. Structures of the phytoligands (1–15) under investigation were built in silico, then subjected to default energy minimization and geometry optimization. The ligand placement was set to apply triangular matcher algorithm. Top five conformers of the test ligands that possessed nonredundant poses of the lowest binding energy were generated by utilizing alpha HB as the default scoring function. An induced fitting protocol for docking was employed to record the best possible molecular interactions [17]. Phytoligands were then ordered according to their S-scores with a root-mean-square deviation (RMSD) value < 2 Å in addition to the graphical representations of the ligand interactions.
Prediction of physicochemical properties, ADMET & drug-likeness parameters

Physicochemical properties and drug-likeness were computed by SwissADME software [18]. ADME profiling was performed by PreADMET calculator [19]. The workflow of the research methodology is illustrated in Figure 2.

Results

Molecular docking analysis of Phlomis aurea phytoligands

Viral infections are generally initiated with the binding of viral particles to specific host-cell surface receptors. Hence, receptor recognition is considered as a critical determinant of the viral entry and cell invasion. Targeting such process is, therefore, considered an inspiring prophylactic approach against viral infection. In SARS-CoV-2, the viral entry is mediated by an envelope-embedded surface-located spike (S) glycoprotein [20] which utilizes hACE2 for cell entry [21]. The S glycoprotein is cleaved, in most cases, by host cell proteases into S1 and S2 subunits for receptor recognition and cell membrane fusion, respectively. S1 is further subdivided into N-terminal domain and C-terminal domain (CTD), both can function as a receptor-binding entity. Most recently, a pioneer study utilized immunostaining and flow cytometry assays to first identify the S1 CTD of SARS-CoV-2 as the key region that interacts with the hACE2 receptor. A 2.5-A° crystal structure of SARS-CoV-2-CTD in complex with a single hACE2 molecule in asymmetric unit (PDB ID: 6LZG) [16] was solved revealing a clear receptor-binding mode. Further analysis of the virus–receptor interaction on structural basis was performed to identify the key aminoacids involved in complex formation. Accordingly, a series of hydrophilic residues forming an H-bonds network and salt bridge interactions were located along the binding interface [16].

In light of the mentioned information we utilized docking simulation to probe the ability of the studied phytoligands to destabilize the virus–receptor complex or even prevent its formation, where possible accommodation/fitting of such phytochemicals at the SARS-CoV-2-CTD-h2ACE interface and their interaction with the complex key amino acids may provide preliminary promising insights for further biological investigation. Several in silico studies displayed the possible inhibitory mechanisms of various phytochemicals on the ACE2–Spike complex of SARS-CoV-2, and highlighted the structural determinants of important interactions [22–26]. In absence of a cocrystalized inhibitor at the interface of the studied complex, we employed the 'site finder' feature of MOE 2015.10 to locate the most suitable site for docking the studied phytochemicals into the SARS-CoV-2-CTD-2hACE binding interface taking in consideration the key residues involved in the complex formation. Flexible docking of the 15 phytochemicals under investigation was performed several times in the defined site at the binding interface with hesperidin as a reference viral entry inhibitor [27].

Docking simulations results (Table 1) showed that most of the studied phytoligands displayed good binding affinities compared with hesperidin (16). Acteoside (11) came at the top of the list recording the best binding affinity (-7.75 kcal/mol) among the studied phytoligands, even better than hesperidin (-7.10 kcal/mol).

Liriodendrin (15), acacetin-7-O-β-glucopyranoside (12), phlomurin (2), 2-phenylethyl-O-β-xylopyranosyl-(1→2)-β-glucopyranoside (10), Syringin (9), benzyl alcohol-O-β-xylopyranosyl-(1→2)-β glucopyranoside (4), phlomuroside (3) and luteolin-7-O-β-glucopyranoside (13) showed slightly less binding affinities ranging from
In silico study of potential anti-SARS cell entry phytoligands from *Phlomis aurea*  

**Table 1. Docking simulations results of the studied phytoligands (1–15) from Phlomis aurea.**

| n  | Name of phytoligands                  | \( \Delta G^\circ \) (kcal/mol) | Interactions at the binding interface† | hACE2 residues | SARSCoV-2-CTD residues |
|----|--------------------------------------|----------------------------------|---------------------------------------|---------------|------------------------|
| 1  | 3-Epiphlomurin                        | -4.70                            | Not studied                           | Not studied   | Not studied            |
| 2  | Phlomurin                             | -6.65                            | Glu37                                 | Arg403, Arg408|                        |
| 3  | Phlomuroside                          | -6.07                            | Glu37                                 | Glu406, Arg408|                        |
| 4  | Benzyl alcohol-O-β-xylopyranosyl-(1→2)-β-glucopyranoside | -6.23 | Glu37, Lys353 | Tyr453, Gly496, Tyr505 |
| 5  | Auroside                              | -3.73                            | Not studied                           | Not studied   |                        |
| 6  | Lamiide                               | -5.72                            | His34, Glu37                          | Glu406, Tyr453|                        |
| 7  | 8-Epiloganin                          | -3.83                            | Not studied                           | Not studied   |                        |
| 8  | Ipolamiide                            | -5.68                            | No interactions                       | No interactions|                        |
| 9  | Syringin (eleutheroside B)            | -6.40                            | No interactions                       | No interactions|                        |
| 10 | 2-Phenylethyl-O-β-xylopyranosyl-(1→2)-β-glucopyranoside | -6.50 | No interactions | Glu406, Gln409 |
| 11 | Acteoside (verbascoside)              | -7.75                            | No interactions                       | Glu406, Arg408, Gln493, Ser494, Gly496 |
| 12 | Chrysoeriol-7-O-β-glucopyranoside     | -6.72                            | No interactions                       | Tyr453, Gly496|                        |
| 13 | Acacetin-7-O-β-glucopyranoside        | -6.06                            | His34, Lys353                         | Tyr453, Ser494, Gly496 |
| 14 | Luteolin-7-O-β-glucopyranoside        | -6.73                            | His34, Lys353                         | Tyr453, Ser494, Gly496 |
| 15 | Liriodendrin (syringaresinol-di-O-glucoside) | -5.97 | No interactions | Arg403, Glu406, Arg408 Gln409, Lys417 |
| 16 | Hesperidin                            | -7.10                            | His34, Ala387                         | Gln409, Lys417, Ser494 |

†The best ligand–receptor complex binding free energy at RMSD <2 Å.
‡The key residues involved in the SARS-CoV-2-CTD-2hACE complex formation are listed in bold.

Moderate fitting was observed in case of the three phytoligands *viz.* chrysoeriol-7-O-β-glucopyranoside (15), lamiide (6) and ipolamiide (8) with binding affinities of -5.97, -5.72 and -5.68 kcal/mol, respectively. The remaining phytoligands showed low binding affinities.

**Interaction of Phlomis phytoligands with human SARS-CoV-Spike-ACE2 complex**

Some of the studied phytoligands showed promising *in silico* results upon inspecting their binding modes with human SARS-CoV-Spike-ACE2 complex. They were able to efficiently accommodate into the interface and interact with the key aminoacids mostly via hydrogen bonding (Figures 3 & 4). Hence, they can destabilize the virus–receptor complexation which is dominated by polar bonding interactions with key hydrophilic amino acid residues [16]. Acteoside (11), a phenolic glycoside recording the best binding affinity in the current study, exhibited hydrogen bonding interactions with Gly496 of the SARS-CoV-2-CTD engaged in complex formation (Figure 3K & L). Additionally, it displayed hydrogen bonding with the nearby amino acids, in other words, Glu406, Arg408, Gln493 and Ser494 on the SARS-CoV-2-CTD side of the interface. These interactions were posed by the sugar hydroxyl groups for Glu406 and Arg408; whereas, Gln493 and Ser494 interacted with the phenolic hydroxyl groups. This highlights that sugar hydroxyl groups and the phenolic hydroxyl groups are the important structural features of the phytoligand. Obviously, acteoside (11) did not show any interactions with hACE2 residues of SARS-CoV-Spike-ACE2 complex as compared with the reference hesperidin (16) which displayed π–π and hydrogen bonding interactions with hACE2 His34 and Ala387, respectively, in addition to its binding to SARS-CoV-2-CTD Gln409, Lys417, Ser494 (Figure 3U & V).

**In silico prediction of physicochemical properties, ADMET & drug-likeness parameters of the most promising phytoligands**

Recently, *in silico* prediction studies of physicochemical properties, ADMET and drug-likeness parameters are utilized for the identification of the most promising leads. Herein, *SwissADME* software was employed to compute the physicochemical properties formulating drug-likeness parameters of the hit phytochemicals (Table 2) [18,28].

**Discussion**

As revealed from our results, acteoside (11) did not inhibit ACE2, which is an added value to its promising anti-SARS-CoV2 potential as the ACE2 inhibition is unfavorable to COVID-19 patients with already developed
Figure 3. Docking simulations of the studied phytochemicals into the binding interface of SARS-CoV-2-CTD in complex with hACE2 (PDB ID: 6LZG). (A & B) 3D and 2D binding modes of 2 (cyan sticks). (C & D) 3D and 2D binding modes of 3 (yellow sticks). (E & F) 3D and 2D binding modes of 4 (magenta sticks). (G & H) 3D and 2D binding modes of 6 (orange sticks). (I & J) 3D and 2D binding modes of 10 (pink sticks). (K & L) 3D and 2D binding modes of 11 (green sticks). (M & N) 3D and 2D binding modes of 12 (deep pink sticks). (O & P) 3D and 2D binding modes of 13 (white sticks). (Q & R) 3D and 2D binding modes of 14 (red sticks). (S & T) 3D and 2D binding modes of 15 (deep yellow sticks). (U & V) 3D and 2D binding modes of 16 (blue sticks) in the binding interface of SARS-CoV-2-CTD in complex with hACE2 (PDB ID: 6LZG). The names of phytoligands (1–15) are given in experimental section.
In silico study of potential anti-SARS cell entry phytoligands from *Phlomis aurea*

Short Communication

Figure 3. Docking simulations of the studied phytochemicals into the binding interface of SARS-CoV-2-CTD in complex with hACE2 (PDB ID: 6LZG) (cont.). (A & B) 3D and 2D binding modes of 2 (cyan sticks). (C & D) 3D and 2D binding modes of 3 (yellow sticks). (E & F) 3D and 2D binding modes of 4 (magenta sticks). (G & H) 3D and 2D binding modes of 6 (orange sticks). (I & J) 3D and 2D binding modes of 10 (pink sticks). (K & L) 3D and 2D binding modes of 11 (green sticks). (M & N) 3D and 2D binding modes of 12 (deep pink sticks). (O & P) 3D and 2D binding modes of 13 (white sticks). (Q & R) 3D and 2D binding modes of 14 (red sticks). (S & T) 3D and 2D binding modes of 15 (deep yellow sticks). (U & V) 3D and 2D binding modes of 16 (blue sticks) in the binding interface of SARS-CoV-2-CTD in complex with hACE2 (PDB ID: 6LZG). The names of phytoligands (1–15) are given in experimental section.
Figure 3. Docking simulations of the studied phytochemicals into the binding interface of SARS-CoV-2-CTD in complex with hACE2 (PDB ID: 6LZG) (cont.). (A & B) 3D and 2D binding modes of 2 (cyan sticks). (C & D) 3D and 2D binding modes of 3 (yellow sticks). (E & F) 3D and 2D binding modes of 4 (magenta sticks). (G & H) 3D and 2D binding modes of 6 (orange sticks). (I & J) 3D and 2D binding modes of 10 (pink sticks). (K & L) 3D and 2D binding modes of 11 (green sticks). (M & N) 3D and 2D binding modes of 12 (deep pink sticks). (O & P) 3D and 2D binding modes of 13 (white sticks). (Q & R) 3D and 2D binding modes of 14 (red sticks). (S & T) 3D and 2D binding modes of 15 (deep yellow sticks). (U & V) 3D and 2D binding modes of 16 (blue sticks) in the binding interface of SARS-CoV-2-CTD in complex with hACE2 (PDB ID: 6LZG). The names of phytoligands (1–15) are given in experimental section.
Figure 3. Docking simulations of the studied phytochemicals into the binding interface of SARS-CoV-2-CTD in complex with hACE2 (PDB ID: 6LZG) (cont.). (A & B) 3D and 2D binding modes of 2 (cyan sticks). (C & D) 3D and 2D binding modes of 3 (yellow sticks). (E & F) 3D and 2D binding modes of 4 (magenta sticks). (G & H) 3D and 2D binding modes of 6 (orange sticks). (I & J) 3D and 2D binding modes of 10 (pink sticks). (K & L) 3D and 2D binding modes of 11 (green sticks). (M & N) 3D and 2D binding modes of 12 (deep pink sticks). (O & P) 3D and 2D binding modes of 13 (white sticks). (Q & R) 3D and 2D binding modes of 14 (red sticks). (S & T) 3D and 2D binding modes of 15 (deep yellow sticks). (U & V) 3D and 2D binding modes of 16 (blue sticks) in the binding interface of SARS-CoV-2-CTD in complex with hACE2 (PDB ID: 6LZG). The names of phytoligands (1–15) are given in experimental section.
Table 2. *In silico* predicted physicochemical properties, ADMET and drug-likeness parameters of the promising phytoligands (11, 12 & 14).

| n  | Log P \(^{†}\) | M.Wt \(^{‡}\) | HBA \(^{§}\) | HBD \(^{¶}\) | NROT \(^{#}\) | TPSA \(^{††}\) | S \(^{†‡}\) | HIA \(^{§§}\) | PBB \(^{¶¶}\) | BBB \(^{¶¶\parallel}\) | Caco-2 \(^{†††}\) | MDCK \(^{‡‡‡}\) | CYP3A4 inhibitor | CYP2D6 inhibitor | LD50 \(^{§§§}\) | Lipinski \(^{††††}\) | Veber \(^{###}\) |
|----|--------------|-------------|--------|--------|-------|----------|-----|-------|-----|-------|---------|--------|------------------|------------------|-------|----------|----------|
| 11 | -2.37        | 624.59      | 15     | 9      | 11     | 245.29   | 290.5| 7.67  | 64.28 | 0.031  | 11.10    | 0.045  | yes              | None             | 5000  | 3 violations (M.Wt, HBA, HBD) | 2 violations (TPSA, rotors) |
| 12 | -1.89        | 462.40      | 11     | 6      | 5      | 179.28   | 40.22| 42.14 | 62.67 | 0.034  | 5.02     | 0.317  | yes              | None             | 5000  | 2 violations (HBA, HBD)      | 1 violation (TPSA)  |
| 14 | -2.10        | 448.38      | 11     | 7      | 4      | 190.28   | 85.91| 25.16 | 73.27 | 0.033  | 4.87     | 0.756  | yes              | None             | 5000  | 2 violations (HBA, HBD)      | 1 violation (TPSA)  |

*Log P:* Logarithm of compound partition coefficient between n-octanol and water.

*M.Wt:* Molecular weight.

*HBA:* Number of hydrogen bond acceptors.

*HBD:* Number of hydrogen bond donors.

*NROT:* Number of rotatable bonds.

*TPSA:* Polar surface area. Drug-like TPSA \(<140-150 \text{ A}^2\).

*S:* Aqueous solubility (mg/l).

*HIA:* Human intestinal absorption. HIA values <20% (poorly absorbed), 20–70% (moderately absorbed) and values >70% (well absorbed) [29].

*PBP:* Plasma protein binding. PBP values <90% (poorly bound) and values >90% (strongly bound) [30].

*BBB:* Blood–brain barrier penetration. BBB values <0.1 (low CNS absorption), 0.1–2 (medium CNS absorption) and values >2 (high CNS absorption) [31].

*Caco-2:* Permeability through cells derived from human colon adenocarcinoma. PCaco-2 values <4 nm/s (low permeability), 4–70 nm/s (medium permeability) and values >70 nm/s (high permeability) [32, 33].

*MDCK:* Permeability through Madin–Darby Canine kidney cells. PMDCK values <25 nm/s (low permeability), 25–500 nm/s (medium permeability) and values >500 nm/s (high permeability) [33, 34].

*LD50:* The median lethal dose (mg/Kg). Toxicity classes according to GHS are: Class I: fatal if swallowed (LD50 ≤ 5), Class II: fatal if swallowed (5 < LD50 ≤ 50), Class III: toxic if swallowed (50 < LD50 ≤ 300), Class IV: harmful if swallowed (300 < LD50 ≤ 2000), Class V: may be harmful if swallowed (2000 < LD50 ≤ 5000) and Class VI: nontoxic (LD50 >5000) calculated using the ProToxII (http://tox.charite.de) web server [35].

*Lipinski rule:* Log p ≤ 5, M.Wt ≤ 500 Da, HBA ≤ 10 and HBD ≤ 5 [36].

*Veber rule:* NROT ≤ 10 and TPSA ≤ 140 [37].
In silico study of potential anti-SARS cell entry phytoligands from *Phlomis aurea*

**Figure 4.** The binding interface of SARS-CoV-2-CTD in complex with hACE2 (PDB ID: 6LZG) showing an overlay of some of the studied phytoligands. *viz.* 2 (cyan sticks), 3 (yellow sticks), 4 (magenta sticks), 6 (orange sticks), 10 (pink sticks), 11 (green sticks), 12 (deep pink sticks), 13 (white sticks), 14 (red sticks), 15 (deep yellow sticks) and 16 (blue sticks). The names of phytoligands (1–15) are given in experimental section.

**Symptoms.** These symptoms develop as a consequence to the decreased production of angiotensin 1–7, which exhibits antifibrotic, anti-inflammatory, vasodilatory actions via Mas receptor [38]. Furthermore, there are preliminary data proving that patients taking angiotensin-II inhibitors (ACE-I) exhibit severe symptoms with a higher mortality rate as compared with their counterparts not taking these medications [39]. Accordingly, ACE2 plays a protective role in the animal models of acute respiratory distress syndrome and acute lung injury [40].

Acteoside (11) occurs frequently in several botanical families *viz.* Scrophulariacea, Lamiacea and Verbenacea [41]. It was reported to exhibit a strong *in vivo* antiviral activity against influenza and antirespiratory syncytial virus which causes the lower respiratory tract infection in infants and young children in addition to other biological actions including antihyperlipidemic, anti-inflammatory, antinociceptive and antioxidant effects [42].

Among the studied phytoligands classes, flavonoids showed the second most promising *in silico* activity among which chrysoeriol-7-β-glucopyranoside (12) interacted with SARS-CoV-2-CTD Gly496 and Tyr453 through the sugar part, but not with hACE2 (Figure 3M & N). Luteolin-7-β-glucopyranoside (14) interacted with Tyr453, Ser494 and Gly496 at the SARS-CoV-2-CTD via the sugar hydroxyl groups; whereas, it was bound to ACE2 at His34 and Lys353 through the aromatic ring and the sugar hydroxyl group, respectively (Figure 3Q & R). Liriodendrin (Syringaresinol-di-β-glucoside) (15) exhibited hydrogen bonding with Arg403, Glu406, Arg408, Gln409 and the key Lys417 at the SARS-CoV-2-CTD side without binding to hACE2 residues (Figure 3S & T).

It is worth noting that acacetin-7-β-glucopyranoside (13) has been reported to exhibit anti-inflammatory action [43,44] with well-proven efficacy against chronic obstructive pulmonary disease via inhibiting neutrophilic lung inflammation in a murine model of chronic obstructive pulmonary disease [45].

Interestingly, the flavonoid, luteolin-7-β-glucopyranoside (14) and the lignan, liriodendrin (15) interacted with the key His34 and Lys353 of the hACE2 via π–π and hydrogen bonding interactions, respectively (Figure 3O–R). It is worth mentioning that a single Lys355 mutation was reported to be sufficient to abolish the interactions at the interface. Both compounds also displayed hydrogen bonding with Tyr453, Ser494 and Gly496 of SARS-CoV-2-CTD at the interface. Benzyl alcohol-β-glucopyranosyl-(1→2)-β-glucopyranoside (4) interacted with SARS-CoV-2-CTD Tyr453, Gly496 and Tyr505 as well as hACE2 Glu37 and Lys353 (Figure 4 E & F). Liriodendrin (15) was reported to exhibit protective role in sepsis-induced acute lung injury via diminishing the release of many proinflammatory mediators, *viz.* TNF-α, IL-1β, MCP-1, and IL-6 and lung myeloperoxidase accumulation in addition to suppressing the VEGF expression and NF-κB activation in the lung [46].
Among the studied iridoids (1, 2, 5–8), only lamiide (6) exhibited similar interactions with hACE2 Glu37 and Lys353 besides engaging SARS-CoV-2-CTD Glu406 and Tyr453 (Figure 3G & H). However, phlomurin (2) in addition to the megastigmane glucoside, phlomuroside (3) (Figures 3A–D) and the phenylethanoid glycoside, 2-phenylethyl-O-β-xylpyranosyl(1→2)-β-glucopyranoside (10) (Figure 3I & J) failed to exhibit interactions with the key aminoacids of the virus–receptor complex however, they could interact with nearby residues. On the other hand, ipolamiide (8) and syringin (9) were able to fit in the binding interface without considerable interactions with its residues.

The phytoligand 'chrysoeriol-7-O-β-glucopyranoside (12) and luteolin-7-O-β-glucopyranoside (14)' showed a slight deviation from the ideal Lipinski’s [47] and Veber’s [37] drug-like bioavailability parameters. According to Lipinski’s rule of five, phytoligands (12 and 14) violated the number of hydrogen bond acceptors and donors. Acteoside (11) recorded an extra Lipinski violation due to its high molecular weight. On the other hand, the studied phytochemicals violated the ideal total polar surface area of the drug-like molecule according to Veber’s parameters (number of rotatable bonds ≤ 10 and total polar surface area ≤ 140). Again, 11 showed one more violation regarding the number of rotor bonds. Pre-ADMET software [19] was employed for prediction of absorption, distribution, metabolism, excretion and toxicity (ADMET) properties of the studied natural products. 12 and 14 were predicted to display moderate human intestinal absorption. 12 recorded higher predicted absorption percentage (42%) than 14 (25%); whereas, 11 was predicted to be poorly absorbed recording only 7.6% intestinal absorption. The three phytochemicals recorded good aqueous solubility. 11 was predicted to be the most readily soluble compound among the group (S = 290.5 mg/l), followed by 14 (S = 85.91 mg/l) and 12 (S = 40.22 mg/l), respectively. This refers to the expected feasibility of the studied phytochemicals to be formulated in various pharmaceutical dosage forms. The three phytochemicals displayed comparable low CNS absorption as detected by their predicted blood–brain barrier penetration values (around 0.03). Thus, the compounds are expected to display limited possible CNS side effects. The compounds displayed medium Caco-2 model and low MDCK model permeabilities. 11 recorded the highest Caco-2 model permeability value (almost two-fold) compared with 12 and 14. On the other hand, 14 was predicted to be two-fold more absorbable by MDCK than 12. 11 displayed the least MDCK permeability value among the group. Interestingly, all compounds were considered poorly bound to plasma proteins (PPB ranges from 62 to 73%) indicating that much of the unbound compound will be available for transport across various membranes to display its pharmacological activities. They were predicted to be devoid of cytochromes P450 2D6 (CYP2D6) inhibition activities but not CYP3A4, addressing the possibility of limited predicted drug interactions. Finally, the median lethal dose (LD50; mg/kg) of the studied compounds in rodents was predicted employing ProTox [35], the toxicity predictor program, to be 5000 mg/kg; thus, classified according to the Globally Harmonized System of Classification and Labeling of Chemicals (GHS) as class V concerning acute oral toxicity.

**Conclusion**

In the current study, we conducted docking simulation to predict the in silico inhibitory potential of a set of 15 phytoligands previously isolated Phlomis aurea, a wild Sinai peninsula plant, against the functional activity of SARS-CoV-Spike-ACE2 complex. Among the studied phytoligands, the phenolic glycoside ‘acteoside (11)’ showed the most potent in silico inhibitory action with an additional merit, over the reference hesperidin (16), of not binding to ACE2 which was reported recently to possess a pulmonary protective role in acute lung injury and acute respiratory distress syndrome in vivo. The second most active phytoligands were flavonoids viz. acacetin-7-O-β-glucopyranoside (13), chrysoeriol-7-O-β-glucopyranoside (12), followed by the lignan ‘liriiodendrin (15)’ and the iridoid ‘lamiide (6)’.

Our results provide promising leads from Phlomis aurea plant for designing and developing drug candidates with phytoprophylactic potential against COVID-19. Besides, pulmonary inflammation and fibrosis are recognized now as the first death causes of COVID-19 patients [48].

The role of anti-inflammatory agents in the effective management of symptoms during COVID-19 has been suggested by clinical practitioners [2]. Interestingly, three of the most active phytoligands in our study have well reported anti-inflammatory actions such as acteoside (11), acacetin-7-O-β-glucopyranoside (13), liriiodendrin (15), with the former compound possessed antifibrotic action additionally. Accordingly, these phytoligands could aid in developing multitargeted strategy for better management and reducing the likelihood of COVID-19 using phytomedicines. Moreover, preparation of quality controlled P. aurea leaf extract aiming to possess highest levels of these phytoligands is warranted. However, in vitro and in vivo experimentation now follows in order to validate the predicted antiviral potential of the most promising phytoligands in P. aurea and/or its leaf extract standardized to
the therapeutic levels of these phytoligands. The predicted ADME and drug-likeness parameters were computed for the three most promising phytochemicals (11, 12 & 14). Results showed that chrysoeriol-7-O-β-glucopyranoside (12) and luteolin-7-O-β-glucopyranoside (14) recorded relatively better predicted drug-like criteria compared with acteoside (11). Thus, these phytochemicals deserve to be further subjected to in vivo pharmacokinetic studies on experimental animals.

Summary points

- In silico analysis of 15 Phlomis aurea phytoligands against SARS-CoV-Spike-ACE2 complex.
- Acteoside possessed the most potent in silico inhibition without binding to ACE2.
- The study posed some phytoligands with prophylactic potential against COVID-19.
- 7-O-β-glucopyranosides of chrysoeriol and luteolin possessed optimum drug-like criteria.

Author contributions

All authors contributed to the study conception and design. Material preparation and data collection were performed by AR Khattab and MS Kamel. Methodology, software, formal analysis, data curation, writing – original draft was performed by M Teleb. The first draft of the manuscript was written by AR Khattab and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

References

1. Sayed AM, Khattab AR, Asmaa M, AboulMagd HMH, Rateb ME, Zaid H, Abdelmohsen UR. Nature as a treasure trove of potential anti-SARSCoV drug leads: a structural/mechanistic rationale. RSC Adv. 10(34), 19790–19802 (2020).
2. Singh SP, Pritam M, Pandey B, Yadav TP. Microstructure, pathophysiology, and potential therapeutics of COVID-19: a comprehensive review. J. Med. Virol. 95(1), 275–299 (2020).
3. Ojha PK, Kar S, Krishna JG, Roy K, Leszczynski J. Therapeutics for COVID-19: from computation to practices – where we are, where we are heading to. Mol. Divers. 25(1), 625–659 (2021).
4. Chilamakuri R, Agarwal S. COVID-19: characteristics and therapeutics. Cels 10(2), 206 (2021).
5. Bright Bisi, Babalola Peace Chinedum, Sam-Agudu Adjoa Nadia, et al. COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. Global Health 17(1), 1–14 (2021).
6. Romani D, Noureddine O, Issaoui N, Brandan SA. Properties and reactivities of niclosamide in different media, a potential antiviral to treatment of COVID-19 by using DFT calculations and molecular docking. Biointerface Res. Appl. Chem. 10(6), 7295–7328 (2020).
7. Sagaama A, Brandan SA, Ben Issa T, Issaoui N. Searching potential antiviral candidates for the treatment of the 2019 novel coronavirus based on DFT calculations and molecular docking. Helixyn 6(8), e04640 (2020).
8. Noureddine O, Issaoui N, Al-Dossary O. DFT and molecular docking study of chloroquine derivatives as antiviral to coronavirus COVID-19. J. King Saud. Univ. 11(1), 101248 (2021).
9. Noureddine O, Issaoui N, Medimagh M, Al-Dossary O, Marouani H. Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: molecular docking and DFT calculations. J. King Saud. Univ. 33(2), 101334 (2021).
10. El Hawary SS, Khattab AR, Marzouk HS et al. In silico identification of SARS-CoV-2 spike (S) protein-ACE2 complex inhibitors from eight Tecoma species and cultivars analyzed by LC-MS. RSC Adv. 10(70), 43103–43108 (2020).
11. Ullah R. Analysis of the fatty acid composition of Phlomis bracteosa oil by gas chromatography-mass spectrometer. Life Sci. J. 10(Suppl. 7), 959–962 (2013).
12. Shaltout KH, Ahmed DA, Shabana HA. Distribution of the species associated with Phlomis aurea Decne along an elevation gradient in southern Sinai, Egypt. Ecol. Mediterr. 42(1), 65–77 (2016).
13. Amor Ben IL, Boubaker J, Sgazer MB et al. Phytochemistry and biological activities of Phlomis species. J. Ethnopharmacol. 125(2), 183–202 (2009).
14. Özcelik B, Orhan I, Kartal M, Konuklagil B. *In vitro* testing of antiviral, antibacterial, antifungal effects and cytotoxicity of selected Turkish *Phlomis* species. *Acta Aliment.* 39(2), 119–125 (2010).

15. Kamel MS, Mohamed KM, Hassanane HA, Ohtani K, Kasai R, Yasamaki K. Iridoid and megastigmane glycosides from *Phlomis aurea*. *Phytochemistry* 55(4), 353–357 (2000).

16. Wang Q, Zhang Y, Wu L et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. *Cell* 181(4), 894–904.e9 (2020).

17. Elhawary SS, Younis IY, El Bishbishy MH, Khattab AR. *LC–MS/MS* based chemometric analysis of phytochemical diversity in 13 *Ficus* spp. (Moraceae): correlation to their *in vitro* antiviral and *in silico* quorum sensing inhibitory activities. *Ind. Crops Prod.* 126, 261–271 (2018).

18. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* 7(1), 1–13 (2017).

19. Lee SK, Park SH, Lee IH, No K. PreAD-MET Ver. v2.0. BMDRC, Seoul, Korea (2007).

20. Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining “host jump” of coronaviruses SARS-CoV, MERS-CoV, and beyond. *Trends Microbiol.* 23(8), 468–478 (2015).

21. Zhou P, Yang X-L, Wang XG et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 579(7798), 270–273 (2020).

22. Teli DM, Mamta B, Shah MB, Chhabria MT. *In silico* screening of natural compounds as potential inhibitors of SARS-CoV-2 main protease and spike RBD: targets for COVID-19. Frontiers in molecular biosciences. *Front. Mol. Biosci.* 7, 429 (2021).

23. Nag Anish, Paul Subhambra, Banerjee Ritesh, Kundu R. *In silico* study of some selective phytochemicals against a hypothetical SARS-CoV-2 Spike RBD using molecular docking tools. *Comput. Biol. Med.* 137, 104818 (2021).

24. Vetrivel Umashankar, Deshpande Sanjay, Harsha V. Hegde, Ishwar Singh and DC. Phytochemical moieties from Indian traditional medicine for targeting dual hotspots on SARS-CoV-2 spike protein: an integrative *in silico* approach. *Front. Med.* 8, 545 (2021).

25. Dey Dipjyoti, Dey Nirban, Ghosh Shalini, Chandrasekaran Narrajan, Mukherjee Amitava, Thomas J. Potential combination therapy using twenty phytochemicals from twenty plants to prevent SARS-CoV-2 infection: an *in silico* approach. *Virodisease* 32(1), 108–116 (2021).

26. Pushkaran Anjia ChooraKotayil, Anu R. Melge, Rammanoar Pathiyedath and CGM. A phytochemical-based medication search for the SARS-CoV-2 infection by molecular docking models towards spike glycoproteins and main proteases. *RSC Adv.* 11(20), 12003–12014 (2021).

27. Wu C, Liu Y, Yang Y et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharm. Sin.* B 10(5), 766–788 (2020).

28. Shady NH, Khattab AR, Ahmed S et al. Hepatitis c virus n3 protease and helicase inhibitors from red sea sponge (*Amphimedon* spp.) in green synthesized silver nanoparticles assisted by *in silico* modeling and metabolic profiling. *Int. J. Nanomedicine* 15, 3377–3389 (2020).

29. Yee S. *In vitro* permeability across Caco-2 cells (colonic) can predict *in vivo* (small intestinal) absorption in man - fact or myth. *Pharm. Res.* 14(6), 765–766 (1997).

30. Prayong P, Barusrux S, Weerapreeyakul N. Cytotoxic activity screening of some indigenous Thai plants. *Firotipis* 79(7–8), 598–601 (2008).

31. Ma XL, Chen C, Yang J. Predictive model of blood-brain barrier penetration of organic compounds. *Acta Pharmacol. Sin.* 26(4), 500–512 (2005).

32. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, T okuda H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. *Eur. J. Pharm. Sci.* 10(3), 195–204 (2000).

33. Irving JD, Takahashi L, Lockhart K et al. MDCK (Madin–Darby canine kidney) cells: a tool for membrane permeability screening. *J. Pharm. Sci.* 88(1), 28–33 (1999).

34. Yazdanian M, Glynn SL, Wright JL, Hawi A. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. *Pharm. Res.* 15(9), 1490–1494 (1998).

35. Banerjee Priyanka, Andreas O. Eckert, Anna K. Schrey and RP. ProT ox-II: a webserver for the prediction of toxicity of chemicals. *Appl. Environ. Microbiol.* 74(2), W257–W263 (2018).

36. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.* 64(Suppl.), 4–17 (2012).

37. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. *J. Med. Chem.* 45(12), 2615–2623 (2002).

38. Abassi ZA, Skorecki K, Heyman SN, Kinane S, Armaly Z. COVID-19 infection and mortality: a physiologist’s perspective enlightening clinical features and plausible interventional strategies. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 318(5), L1020–L1022 (2020).

39. Jakovac H. COVID-19: is the ACE2 just a foe? *Am. J. Physiol. Lung Cell. Mol. Physiol.* 318(5), L1025–L1026 (2020).
In silico study of potential anti-SARS cell entry phytoligands from *Phlomis aurea*  

Short Communication

40. Imai Y, Kuba K, Rao S et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* 436(7047), 112–116 (2005).

41. Juliani HR, Wang M, Moharram H et al. Intraspecific variation in quality control parameters, polyphenol profile, and antioxidant activity in wild populations of *Lippia multiflora* from Ghana. In: *Herbs: Challenges in Chemistry and Biology* Wang M, Sang S, Hwang LS et al. (Eds). ACS Symposium Series 925, 126–142 (2006).

42. Chathuranga K, Kim MS, Lee HC et al. Anti-respiratory syncytial virus activity of *Plantago asiatica* and *Clerodendrum trichotomum* extracts in vitro and in vivo. *Viruses* 11(7), 604 (2019).

43. Nam KH, Choi JH, Seo YJ et al. Inhibitory effects of Tilianin on the expression of inducible nitric oxide synthase in low density lipoprotein receptor deficiency mice. *Exp. Mol. Med.* 38(4), 445–452 (2006).

44. Hong JJ, Choi JH, Oh SR et al. Inhibition of cytokine-induced vascular cell adhesion molecule-1 expression; possible mechanism for anti-atherogenic effect of *Agastache rugosa*. *FEBS Lett.* 495(3), 142–147 (2001).

45. Kim SH, Hong JH, Yang WK et al. Herbal combinational medication of glycyrrhiza glabra, Agastache rugosa containing glycyrrhizic acid, Tilianin inhibits neutrophilic lung inflammation by affecting CXCL2, interleukin-17/STAT3 signal pathways in a murine model of COPD. *Nutrients* 12(4), 1–31 (2020).

46. Yang L, Li D, Zhuo Y, Zhang S, Wang X, Gao H. Protective role of liriodendrin in sepsis-induced acute lung injury. *Inflammation* 39(5), 1805–1813 (2016).

47. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings (reprinted from *Advanced Drug Delivery Reviews*, vol 23, pg 3–25, 1997). *Adv. Drug Deliv. Rev.* 46(1–3), 3–26 (2001).

48. Conti P, Ronconi G, Caraffa A et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVID-19 or SARS-CoV-2): anti-inflammatory strategies. *J. Biol. Regul. Homeost. Agents* 34(2), 327–331 (2020).